IFN-γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN-γ response

Ding,Guoping; Zhou,Liangjing; Shen,Tao; Cao,Liping

doi:10.3892/ol.2018.7777

IFN-γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN-γ response

Authors:
- Guoping Ding
- Liangjing Zhou
- Tao Shen
- Liping Cao
View Affiliations

Affiliations: Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China
Published online on: January 12, 2018 https://doi.org/10.3892/ol.2018.7777
Pages: 3760-3765

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that pancreatic cancer-derived microRNA (miR)-212-3p can inhibit the expression of regulatory factor X‑associated protein (RFXAP), an important transcription factor for major histocompatibility complex (MHC) class II, and thereby lead to downregulation of MHC class II in dendritic cells. It has also been established that interferon (IFN)‑γ can increase the expression of MHC class II in immune cells. It was therefore hypothesized that IFN‑γ can inhibit miR‑212‑3p expression in pancreatic cancer, leading to the upregulation of RFXAP and MHC class II expression. This may represent a novel molecular mechanism underlying the use of IFN‑γ in immunotherapy. Data from the present study revealed that miR‑212‑3p was inhibited by IFN‑γ in a dose and time‑dependent manner in the pancreatic ductal adenocarcinoma cell line PANC‑1. RFXAP and MHC class II expression were increased following IFN‑γ stimulation. A luciferase assay was performed to validate RFXAP as a target gene of miR‑212‑3p. The expression levels of RFXAP and MHC class II were decreased by miR‑212‑3p mimics and increased by miR‑212‑3p inhibitors. In PANC‑1 cells transfected with miR‑212‑3p mimics, IFN‑γ stimulation could not increase the RFXAP and MHC class II. The results from the present study suggest that IFN‑γ increases RFXAP and MHC class II expression by inhibiting miR‑212‑3p. To the best of our knowledge, this is the first report of this novel molecular mechanism underlying the effects of IFN‑γ on pancreatic cancer, which may aid with the development of immunotherapies for patients with pancreatic cancer.

View Figures

View References

1	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M, Macchia G, et al: A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 17:194–205. 2010. View Article : Google Scholar : PubMed/NCBI
4	Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP and Tu YK: Adjuvant treatments for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. Lancet Oncol. 14:1095–1103. 2013. View Article : Google Scholar : PubMed/NCBI
5	Gaida MM, Welsch T and Herpel E: MHC class II expression in pancreatic tumors: A link to intratumoral inflammation. Virchows Arch. 460:47–60. 2012. View Article : Google Scholar : PubMed/NCBI
6	Sartoris S, Valle MT, Barbaro AL, Tosi G, Cestari T, D'Agostino A, Megiovanni AM, Manca F and Accolla RS: HLA class II expression in uninduciblehepatocarcinoma cells after transfection of AIR-1 gene product CIITA: Acquisition of antigen processing and presentation capacity. J Immunol. 161:814–820. 1998.PubMed/NCBI
7	van Eggermond MC, Tezcan I, Heemskerk MH and van den Elsen PJ: Transcriptional silencing of RFXAP in MHC class II-deficiency. Mol Immunol. 45:2920–2928. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ding G, Zhou L, Qian Y, Fu M, Chen J, Chen J, Xiang J, Wu Z, Jiang G and Cao L: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6:29877–29888. 2015. View Article : Google Scholar : PubMed/NCBI
9	Blanck G: Components of the IFN-gamma signaling pathway in tumorigenesis. Arch Immunol Ther Exp. 50:151–158. 2002.
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Einhorn S and Strander H: Interferon treatment of human malignancies-a short review. Med Oncol Tumor Pharmacother. 10:25–29. 1993.PubMed/NCBI
12	Vihinen P, Tervahartiala T, Sorsa T, Hansson J, Bastholt L, Aamdal S, Stierner U, Pyrhönen S, Syrjänen K, Lundin J and Hernberg M: Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels. Cancer Immunol Immunother. 64:173–180. 2015. View Article : Google Scholar : PubMed/NCBI
13	Boehm U, Klamp T, Groot M and Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol. 15:749–795. 1997. View Article : Google Scholar : PubMed/NCBI
14	Endou M, Mizuno M, Nagata T, Tsukada K, Nakahara N, Tsuno T, Osawa H, Kuno T, Fujita M, Hatano M and Yoshida J: Growth inhibition of human pancreatic cancer cells by human interferon-beta gene combined with gemcitabine. Int J Mol Med. 15:277–283. 2005.PubMed/NCBI
15	Detjen KM, Farwig K, Welzel M, Wiedenmann B and Rosewicz S: Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 49:251–262. 2001. View Article : Google Scholar : PubMed/NCBI
16	Accolla RS, Scupoli MT, Cambiaggi C, Tosi G and Sartoris S: Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. Int J Cancer Suppl. 6:20–25. 1991. View Article : Google Scholar : PubMed/NCBI
17	Garvie CW and Boss JM: Assembly of the RFX complex on the MHCII promoter: Role of RFXAP and RFXB in relieving autoinhibition of RFX5. Biochim Biophys Acta. 1779:797–804. 2008. View Article : Google Scholar : PubMed/NCBI
18	Hanna S and Etzioni A: MHC class I and II deficiencies. J Allergy Clin Immunol. 134:269–275. 2014. View Article : Google Scholar : PubMed/NCBI
19	Scupoli MT, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T, Zamboni G, Martignoni G, Lemoine NR, Scarpa A and Accolla RS: Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens. 48:301–311. 1996. View Article : Google Scholar : PubMed/NCBI
20	Surmann EM, Voigt AY, Michel S, Bauer K, Reuschenbach M, Ferrone S, von Knebel Doeberitz M and Kloor M: Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunol Immunother. 64:357–366. 2015. View Article : Google Scholar : PubMed/NCBI
21	Gaida MM, Welsch T, Herpel E, Tschaharganeh DF, Fischer L, Schirmacher P, Hänsch GM and Bergmann F: MHC class II expression in pancreatic tumors: A link to intratumoral inflammation. Virchows Arch. 460:47–60. 2015. View Article : Google Scholar
22	Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ and Schmittgen TD: miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 406:518–523. 2011. View Article : Google Scholar : PubMed/NCBI
23	Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H, Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014. View Article : Google Scholar : PubMed/NCBI
24	Ryan DP, Hong TS and Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014. View Article : Google Scholar : PubMed/NCBI
25	Karakhanova S, Ryschich E, Mosl B, Harig S, Jäger D, Schmidt J, Hartwig W, Werner J and Bazhin AV: Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer. 112:1027–1036. 2015. View Article : Google Scholar : PubMed/NCBI